Prevenar

RSS

pneumococcal saccharide conjugated vaccine, adsorbed

Withdrawn
This medicine is now withdrawn from use in the European Union.

Overview

The marketing authorisation for Prevenar has been withdrawn at the request of the marketing authorisation holder.

This EPAR was last updated on 24/11/2017

Authorisation details

Product details
Name
Prevenar
Agency product number
EMEA/H/C/000323
Active substance
  • pneumococcal oligosaccharide serotype 18C
  • Pneumococcal polysaccharide serotype 19F
  • Pneumococcal polysaccharide serotype 23F
  • Pneumococcal polysaccharide serotype 4
  • Pneumococcal polysaccharide serotype 6B
  • Pneumococcal polysaccharide serotype 9V
  • Pneumococcal polysaccharide serotype 14
International non-proprietary name (INN) or common name
pneumococcal saccharide conjugated vaccine, adsorbed
Therapeutic area (MeSH)
  • Pneumococcal Infections
  • Immunization
Anatomical therapeutic chemical (ATC) code
J07AL02
Publication details
Marketing-authorisation holder
Pfizer Limited
Revision
23
Date of issue of marketing authorisation valid throughout the European Union
02/02/2001
Contact address
Ramsgate Road
Sandwich
Kent
CT13 9NJ
United Kingdom

Product information

22/06/2015 Prevenar - EMEA/H/C/000323 - PSUSA/00002452/201408

Other EU languages available icon This medicine’s product information is available in all official EU languages.
Select ‘available languages’ to access the language you need.

 

Product information documents contain:

  • summary of product characteristics (annex I);
  • manufacturing authorisation holder responsible for batch release (annex IIA);
  • conditions of the marketing authorisation (annex IIB);
  • labelling (annex IIIA);
  • package leaflet (annex IIIB).

You can find product information documents for centrally authorised human medicines on this website. For centrally authorised veterinary medicines authorised or updated from February 2022, see the Veterinary Medicines Information website.

Pharmacotherapeutic group

Vaccines

Therapeutic indication

Active immunisation against disease caused by Streptococcus pneumoniae serotypes 4, 6B, 9V, 14, 18C, 19F and 23F (including sepsis, meningitis, pneumonia, bacteraemia and acute otitis media) in infants and children from two months up to five years of age.

The use of Prevenar should be determined on the basis of official recommendations taking into consideration the impact of invasive disease in different age groups as well as variability of serotype epidemiology in different geographical areas.

Assessment history

Changes since initial authorisation of medicine

  • List item

    Prevenar-H-C-PSUSA-00002452-201408 : EPAR - Scientific conclusions and grounds recommending the variation to the terms of the marketing authorisation (PDF/527.72 KB)


    First published: 16/07/2015
    Last updated: 24/11/2017
    EMA/CHMP/722875/2014

  • List item

    Prevenar-H-C-323-P46-0130 : EPAR - Assessment Report (PDF/1.06 MB)

    Adopted

    First published: 23/02/2015
    Last updated: 24/11/2017
    EMA/124579/2015

  • List item

    Prevenar-H-C-323-P46-0132 : EPAR - Assessment Report (PDF/2.48 MB)

    Adopted

    First published: 23/02/2015
    Last updated: 24/11/2017
    EMA/125121/2015

  • List item

    Prevenar-H-C-323-P46-0129 : EPAR - Assessment Report (PDF/1.05 MB)

    Adopted

    First published: 19/02/2015
    Last updated: 24/11/2017
    EMA/123675/2015

  • List item

    Prevenar-H-C-323-II-76 : EPAR - Scientific Discussion - Variation (PDF/635.94 KB)

    Adopted

    First published: 29/08/2007
    Last updated: 24/11/2017

  • List item

    Prevenar-H-C-323-II-80 : EPAR - Scientific Discussion - Variation (PDF/673.49 KB)

    Adopted

    First published: 29/08/2007
    Last updated: 24/11/2017

  • List item

    Prevenar : EPAR - Steps taken after authorisation when a cutoff date has been used (PDF/563.25 KB)


    First published: 21/10/2005
    Last updated: 24/11/2017

    How useful was this page?

    Add your rating